T2 Biosystems Inc. (NASDAQ:TTOO) saw strong trading volume on Monday . 625,582 shares were traded during trading, an increase of 152% from the previous session’s volume of 248,522 shares.The stock last traded at $6.94 and had previously closed at $5.66.

Several research analysts have commented on the company. Canaccord Genuity restated a “buy” rating on shares of T2 Biosystems in a report on Sunday, May 29th. Janney Montgomery Scott restated a “hold” rating on shares of T2 Biosystems in a report on Saturday, July 9th. Cantor Fitzgerald restated a “buy” rating on shares of T2 Biosystems in a report on Saturday, July 9th. Leerink Swann restated a “buy” rating on shares of T2 Biosystems in a report on Sunday, July 10th. Finally, Zacks Investment Research downgraded T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, July 27th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $11.03.

The firm’s market capitalization is $170.96 million. The firm has a 50 day moving average price of $6.94 and a 200-day moving average price of $8.42.

T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.02. During the same quarter in the prior year, the company earned ($0.54) earnings per share. The firm earned $0.99 million during the quarter, compared to analyst estimates of $1.53 million. The company’s revenue for the quarter was up 75.5% on a year-over-year basis. Equities analysts expect that T2 Biosystems Inc. will post ($2.17) earnings per share for the current fiscal year.

In other news, SVP Rahul Dhanda sold 3,589 shares of the company’s stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $8.16, for a total transaction of $29,286.24. Following the sale, the senior vice president now owns 3,589 shares of the company’s stock, valued at $29,286.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC raised its stake in shares of T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems makes up 5.3% of Aisling Capital LLC’s holdings, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 as of its most recent filing with the SEC.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.